Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Summary

This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin) administered concurrent to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma) having platinum-sensitive relapse (platinum-free interval \> 6 months).

Timeline

Start

2022-02-22

Primary completion

2026-03-01

Completion

2028-03-01

Publications

• Pruss M, Bommert M, Ehmann S, Temizel-Kanbur F, Welz J, Kaiser S, Westermann T, Karabeg E, Zdanyte K, Strojna A, Traut A, Heitz F, Harter P, Moubarak M. Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experience. Int J Gynecol Cancer. 2025 Dec;35(12):102672. doi: 10.1016/j.ijgc.2025.102672. Epub 2025 Sep 27.

Drugs

Indications